Affiliation:
1. Institute for Cell Engineering Johns Hopkins University School of Medicine Baltimore MD 21205 USA
2. Department of Neurology Johns Hopkins University School of Medicine Baltimore MD 21205 USA
3. The Solomon Snyder Department of Neuroscience Johns Hopkins University School of Medicine Baltimore MD 21205 USA
Abstract
AbstractParkinson's disease (PD) is one of the most devastating neurological diseases; however, there is no effective cure yet. The availability of human induced pluripotent stem cells (iPSCs) provides unprecedented opportunities to understand the pathogenic mechanism and identification of new therapy for PD. Here a new model system of PD, including 2D human iPSC‐derived midbrain dopaminergic (mDA) neurons, 3D iPSC‐derived midbrain organoids (MOs) with cellular complexity, and more advanced microphysiological systems (MPS) with 3D organoids, is introduced. It is believed that successful integrations and applications of iPSC, organoid, and MPS technologies can bring new insight on PD's pathogenesis that will lead to more effective treatments for this debilitating disease.
Funder
National Institute of Neurological Disorders and Stroke
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献